Advances in stem cell transplantation: making it better and safer.
The development of reduced-intensity regimens has allowed physicians and patients to explore this option even in older patients. Current results underscore that age by itself should no longer be a contraindication for allogeneic transplantation in these patients, and long-term disease control with good quality of life is possible. Future trials combining novel antileukemic therapies and novel transplantation technologies are being explored. These trials should allow more patients with acute myeloid leukemia or myelodysplastic syndromes to achieve long and productive lives.